Sermorelin & Ipamorelin Blend: The Synthetic Analogues Of The Human Growth Hormone

by | Aug 19, 2022 | Research


Ipamorelin & Sermorelin Blend

Natural growth hormones may elevate when Ipamorelin is combined with Sermorelin. This is because sermorelin has different mechanisms of action in the pituitary gland than Ipamorelin. As a result, a higher growth hormone level is obtained when Ipamorelin blends with sermorelin. Studies have shown that this may improve wound healing and recovery and cause faster muscle repair and muscle growth.


What is Ipamorelin and Its Functions?

Ipamorelin is the most direct ghrelin analog or agonist of the human growth hormone secretagogue. The peptide increases serum GH levels in humans and animals.[1]

Ipamorelin stimulates the pituitary gland-based secretion of growth-related secretions. It is known for skeletal and muscular tissue growth and repair. Ipamorelin produces the most growth hormone when combined with Sermorelin. The combination enhances the effects of human growth hormone on cardiovascular balance, brain health, metabolic functions, and muscle growth.

Ipamorelin stimulates the production of insulin-like growth factor 1 (IGF-1) in the body, which improves strength, promotes recovery, increases lean muscle mass, and boosts tissue recovery. Ipamorelin prevents the adverse effects of synthetic HGH administration, such as the inhibition of natural growth hormone synthesis, in this mode of action.

According to studies, Ipamorelin does not affect cortisol, appetite, or prolactin levels.[3] The researchers also reported that “ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.” 


What is Sermorelin and Its Functions

Sermorelin is a growth hormone analog that mimics the positive effects of GHRH while avoiding the negative effects. Sermorelin, like the body’s natural GHRH mechanism, binds to the growth hormone-releasing hormone receptor (GHRHr) in the anterior pituitary gland.[4] The peptide increases endogenous IGF-1 secretion while promoting robust growth hormone production.

A negative feedback mechanism induced by somatostatin controls the positive effect of Sermorelin on the release of the human growth hormone. Somatostatin is a growth-inhibiting hormone (GHIH) that inhibits the secretion of other hormones in the endocrine system as well as certain exocrine secretions. This mechanism has a positive impact because it prevents extreme, unhealthy GH levels in the body and mimics more natural patterns of fluctuation in GH concentrations.

Furthermore, sermorelin’s natural action mechanism preserves the hypothalamic-pituitary-somatotropic axis, preventing the cessation of direct replacement with hGH.

Sermorelin is used in clinical settings because of its ability to influence growth hormone secretion.[5] The researchers report that “Sermorelin stimulates pituitary gene transcription of hGH messenger RNA, increasing pituitary reserve and thereby preserving more of the growth hormone neuroendocrine axis, which is the first to fail during aging.” The peptide may improve bone density, nutrition in chronic illness, renal function, seizure activity, the adverse effects of dementia, and scarring caused by a heart attack. Sermorelin also promotes angiogenesis, reduces cardiomyocyte cell death, and reduces inflammation after cardiac injuries. Sermorelin can also potentially improve sleep quality, the central nervous system, bone health, bowel motility, and diabetes insulin control.Conclusion

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.



  1. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.
  2. Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003 Apr-Jun;4(2):73-81. doi: 10.1155/EDR.2003.73. PMID: 14630569; PMCID: PMC2478601.
  3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
  4. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57. doi: 10.2165/00063030-199912020-00007. PMID: 18031173.
  5. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.
  6. Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021 Mar;9(5):406. doi: 10.21037/atm-20-6561. PMID: 33842627; PMCID: PMC8033379.